Dong-a St Co., Ltd.

Dong-a Socio Holdings Co., Ltd.

Dongsop Lee

Hyounmie Doh

Dongsup Song

Sung-Hee Lee

Dong-Hyeon Kim

Yoojin Kim

Chae Young Kim

Eunee Jung

Kyusang Hwang

Yoo-jin Kim

Byong Moon Kim

Kyung Mi Han

Jinseok Lee

Soyon Woo

Donghyeon Kim

Kyungmi Han

Hanyoung Lee

Kum-Joo Shin

Woo Jin Seung

Eun-ee Jung

Eongsup Song

Eun-Ee Jung

Yoo-Jin Kim

The present invention relates to an antibody that specifically binds to death receptor 5 (DR5) and has a function of killing cancer cells. Specifically, provided are an anti-DR5 antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment for preventing or treating cancer. The present invention is characterized in that the anti-DR5 antibody or antigen-binding fragment thereof is improved in terms of affinity to DR5, stability, and an effect of killing cancer cells.

Anti-DR5 antibody and use thereof

A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.

Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same

Growing community of inventors

Yongin-si, South Korea

Dongsop Lee